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Objective: In contrast to conventional breast imaging techniques, one major
diagnostic benefit of breast magnetic resonance imaging (MRI) is the si-
multaneous acquisition of morphologic and dynamic enhancement charac-
teristics, which are based on angiogenesis and therefore provide insights into
tumor pathophysiology. The aim of this investigation was to intraindividually
compare 2 macrocyclic MRI contrast agents, with low risk for nephrogenic
systemic fibrosis, in the morphologic and dynamic characterization of his-
tologically verified mass breast lesions, analyzed by blinded human evalua-
tion and a fully automatic computer-assisted diagnosis (CAD) technique.
Materials and Methods: Institutional review board approval and patient
informed consent were obtained. In this prospective, single-center study,
45 women with 51 histopathologically verified (41 malignant, 10 benign)
mass lesions underwent 2 identical examinations at 1.5 T (mean time interval,
2.1 days) with 0.1-mmol kgj1 doses of gadoteric acid and gadobutrol. Allmagnetic
resonance images were visually evaluated by 2 experienced, blinded breast
radiologists in consensus and by an automatic CAD system, whereas the
morphologic and dynamic characterization as well as the final human clas-
sification of lesions were performed based on the categories of the Breast
imaging reporting and data system MRI atlas. Lesions were also classified
by defining their probability of malignancy (morpho-dynamic index;
0%Y100%) by the CAD system. Imaging results were correlated with his-
topathology as gold standard.
Results: The CAD system coded 49 of 51 lesions with gadoteric acid and
gadobutrol (detection rate, 96.1%); initial signal increase was significantly
higher for gadobutrol than for gadoteric acid for all and the malignant coded
lesions (P G 0.05). Gadoteric acid resulted in more postinitial washout curves
and fewer continuous increases of all and the malignant lesions compared
with gadobutrol (CAD hot spot regions, P G 0.05). Morphologically, the
margins of the malignancies were different between the 2 agents, whereas
gadobutrol demonstrated more spiculated and fewer smooth margins (P G 0.05).
Lesion classifications by the human observers and by the morpho-dynamic
index compared with the histopathologic results did not significantly differ
between gadoteric acid and gadobutrol.
Conclusions: Macrocyclic contrast media can be reliably used for breast
dynamic contrast-enhanced MRI. However, gadoteric acid and gadobutrol
differed in some dynamic and morphologic characterization of histologically
verified breast lesions in an intraindividual, comparison. Besides the stan-
dardization of technical parameters and imaging evaluation of breast MRI, the
standardization of the applied contrast medium seems to be important to receive
best comparable MRI interpretation.
Key Words: breast MRI, contrast medium, gadoteric acid, gadobutrol,
breast cancer, CAD
(Invest Radiol 2014;49: 474Y484)
B reast carcinoma is the most common cancer in women world-wide.1 Breast dynamic contrast-enhanced magnetic resonance
imaging (DCE-MRI) is gaining wide acceptance as an accurate im-
aging technique for detection, staging, and monitoring of invasive
breast carcinomas.2Y8 Compared with conventional breast imaging
modalities, one major benefit of DCE-MRI is the possibility to ac-
quire morphologic and dynamic enhancement characteristics, which
are based on angiogenesis and provide insights into tumor patho-
physiology.4,9,10 Thus, the intravenous application of contrast media
is essential for reliable lesion detection and diagnosis by breast DCE-
MRI.4,9,10 To standardize imaging evaluation, Breast imaging reporting
and data system (BI-RADS) MRI atlas, which considers morphologic
and dynamic parameters, has been established and reported to reveal
acceptable interobserver agreement.11Y14
To further minimize interobserver variability, computer-assisted
diagnosis (CAD) systems for breast DCE-MRI are increasingly inte-
grated into clinical practice for the assessment of kinetic enhancement
features.15 There is high clinical interest in incorporating also mor-
phologic assessment into CAD systems and in linking computer-
extracted features to the descriptors of the BI-RADS MRI atlas. Some
of the CAD systems for breast DCE-MRI combine morphologic and
dynamic parameters, showing promising results, whereas different
MRI contrast media have been used.16Y20 However, intraindividual,
visually evaluated comparison studies found differences in signal
enhancement, detection, and differentiation between malignant and
benign breast lesions according to the MRI contrast agent used.21Y24
Extracellular gadolinium (Gd)-based MRI contrast media are
categorized into macrocyclic and linear agents owing to their chemical
structures.25,26 The macrocyclic molecules form a rigid ring system,
in which Gd ions are caged, whereas the linear chelates wrap around
the Gd ions.25,26 Compared with linear agents, macrocyclic com-
pounds release less free Gd ions; this higher stability becomes rel-
evant with regard to nephrogenic systemic fibrosis in patients with
impaired renal function, as the macrocyclic chelates are associated
with lower risk of developing this severe systemic disorder.26Y30
Gadoteric acid (Gd-DOTA; Dotarem; Guerbet, Roissy CdG, Cedex,
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France) and gadobutrol (Gd-DO3A-butriol; Gadovist; Bayer Health-
care, Leverkusen, Germany) are both macrocyclic contrast media with
currently lower worldwide application for breast DCE-MRI compared
with conventional linear agents, such as gadopentetate dimeglumine
(Gd-DTPA; Magnevist; Bayer Healthcare). The purpose of this study
was to prospectively and intraindividually compare 0.1 mmol kgj1
body weight doses of gadoteric acid and gadobutrol for the detection
and characterization of histologically confirmed malignant and be-
nign breast masses; to provide as much as possible objective inter-
pretation, magnetic resonance (MR) images were evaluated by blinded
human visual evaluation as well as by a unique fully automatic CAD
system, which analyzed dynamic and morphologic parameters and
linked these features to the BI-RADS descriptors.
MATERIALS AND METHODS
Study Standards and Design
This prospective investigation (clinical trial phase IIIb) was
performed in accordance with the Declaration of Helsinki and was
approved by the local ethics committee and the Federal Institute for
Drugs and Medical Devices (Bonn, Germany). Patients were consec-
utively enrolled over a period of 8 months; all patients gave written
informed consent before study participation.
Female patients were included if they were at least 18 years of
age and had suspicious findings on x-ray mammography and/or ul-
trasonography (BI-RADS categories 4 and 5). The patients were not
part of the government-funded mammography screening program
but received x-ray mammography and ultrasonography for clinical
indications, such as palpable mass, or pain in the breast. After con-
ventional breast imaging, the patients were scheduled for DCE-MRI
for further diagnostic imaging and treatment planning. Another
important inclusion criterion was the presence of mass breast le-
sions, as the used CAD system has been solely evaluated in detail for
mass lesions and the morphologic description of lesions by the CAD
system corresponded to the BI-RADS categories of masses.18 The
reference standard was the histopathologic confirmation of the mass
lesions, whereas experienced breast pathologists performed histo-
pathologic diagnosis. The lesions were categorized by using the
World Health Organization classification of malignant and benign
breast tumors; the grading of carcinomas was specified as well (grade,
G1), moderately (G2), and poorly (G3) differentiated cancers.
Exclusion criteria were the following:
YContraindications to MRI, for example, pacemaker, claustrophobia,
severe obesity;
YApplication of any contrast medium within 24 hours before receiving
gadoteric acid or gadobutrol and between the 2MRI examinations;
YHistory of anaphylactoid or anaphylactic reaction to any contrast
medium;
YPregnant or lactating women;
YClinically unstable condition and/or requirement of emergency treat-
ment and/or physical or mental status, which interfered with
the signing of the informed consent; and
YChronic kidney disease stage 3 or greater, that means glomeru-
lar filtration rate of lower than 60 mL minj1, as 2 contrast
media administrations have to be applied.
All patients received one DCE-MRI examination with
gadoteric acid and one with gadobutrol; the technical MRI parame-
ters of the 2 examinations were identical. Patients were randomized
prospectively into 2 groups (A or B) before breast DCE-MRI. In
group A, gadoteric acid was administered for the first and gadobutrol
for the second examination; group B received the agents in reverse
order. The interval between the 2 MRI examinations was between
24 hours and 7 days; within this period, the patients did not undergo
systemic or local treatment including interventional procedure, such as
breast biopsy, surgery, radiation and/or chemotherapy.
MRI Protocol
Breast DCE-MRI examinations were performed with pre-
defined standardized parameters on a 1.5-T system (Magnetom
Avanto; Siemens Healthcare, Erlangen, Germany) using a 4-channel
bilateral breast coil with the patient in prone position. Three-
dimensional (3D) gradient-echo T1-weighted sequences were ac-
quired precontrast and postcontrast by using the following parameters:
repetition time, 7.5 milliseconds; echo time, 4.8 milliseconds; flip
angle, 25-; field of view (FOV), 320 to 360 mm; acquisition matrix,
384  384; and spatial resolution, 0.7  0.7  2 mm3. Each sequence
comprised of 72 slices in transverse orientation. Acquisition time for
one T1-weighted sequence was 59 to 77 seconds depending on breast
size. Twenty seconds after beginning of contrast medium injection,
dynamic scanning was continued with the same sequence parame-
ters and under identical tuning conditions; 5 postcontrast series were
acquired with identical time intervals. Unenhanced images were sub-
tracted from postcontrast images. In addition, transverse T2-weighted
turbo-spin-echo sequences were performed before contrast medi-
um administration (repetition time, 6750 milliseconds; echo time,
80 milliseconds; flip angle, 150-; FOV, 320Y360 mm; acquisition ma-
trix, 448  448; spatial resolution, 0.7  0.7  2.5 mm3).
Contrast Medium Administration
Gadoteric acid is hydrophilic and negatively charged, with a
Gd concentration of 0.5 mol Lj1. The hydrophilic, neutral contrast
medium gadobutrol contains twice the Gd concentration (1 mol Lj1).
Both agents possess high thermodynamic, kinetic, and conditional
stability as well as lowosmolality and viscosity.25,26 Gadobutrol reveals
an approximately 1.5-fold higher T1 relaxivity (5.2 L mmolj1 sj1 at
37-C in plasma at 1.5 T) compared with 3.6 Lmmolj1 sj1 of gadoteric
acid.31 Both contrast media have been proven as well tolerated with low
rates of adverse events.32,33
Both agents were automatically administered in 0.1-mmol kgj1
doses by a power injector with a flow rate of 2 mL sj1. The contrast
medium injection was followed by a 0.9% sodium chloride solution
with the same flow rate. Because of its doubled Gd concentration and
the equimolar dose, the administered volume of gadobutrol was half
that of gadoteric acid. The volume of the saline flush was therefore
adapted [volume saline flush, 30 mL for gadoteric acid; volume saline
flush for gadobutrol, 30 mL + (volume gadoteric acid j volume
gadobutrol) mL] to equalize the total amount of injection volumes and,
thus, the injection times in both MRI examinations.
Analysis of MR Images
All MR images were visually evaluated by 2 experienced
breast radiologists (7 and 10 years of experience in breast MRI) in
consensus and by an automatic CAD system (Breast MRI Carebox;
Bracco Imaging, Milan, Italy). For visual imaging evaluation, the
2 human blinded readers analyzed the MR images considering the
following viewpoints: detection of contrast-enhanced breast lesions,
detailed morphologic characterization of lesions, visual dynamic
interpretation, and final lesions’ classification. The MR imaging
analysis of the human readers as well as of the CAD system was
performed based on the guidelines of the BI-RADSMRI atlas.11 The
human observers categorized the lesions as benign or malignant
following the ordinal scale of the BI-RADS classification: 1, no
pathologic enhancement; 2, definitely benign; 3 probably benign; 4,
suspicious abnormality; and 5, highly suggestive of malignancy. All
MRI examinations were evaluated by the readers in a blinded,
anonymized manner to clinical and radiological data and in a ran-
domized order, without knowledge of which contrast media had
been applied. Both human observers reviewed the data set for the
first time for study purpose, as they were not involved in the clinical
imaging diagnosis of the patients, to prevent recall bias. The patients
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who fulfilled the specific inclusion criteria were preselected and
enrolled by a clinician radiologist dedicated to breast imaging, who
analyzed the x-ray mammographic, ultrasonographic, and MR im-
ages during clinical routine.
In addition to the description and classification of contrast-
enhancing lesions, the 2 blinded human observers assessed back-
ground enhancement (BE) independently for all MRI examinations
during the study imaging evaluation. This BE, owing to hormonal
effects and mastopathic proliferative disease, was visually deter-
mined by using the ordinal scale of Baltzer et al34: grade 0, no rel-
evant BE; grade 1, moderate BE; and grade 2, distinct BE.
For the CAD imaging evaluation, the dynamic series were
transferred as anonymized DICOM (Digital Imaging and Commu-
nications in Medicine) files to the automatic CAD system. The
specific characteristic of the used CAD technique was that it auto-
matically detected contrast-enhancing breast lesions and performed
dynamic as well as morphologic characterization of the lesions and
linked these descriptions to features, laid down in the BI-RADS
MRI atlas.11,18 The CAD system has been recently described and
evaluated in detail, showing that it can reliably distinguish between
benign and malignant breast mass lesions with a diagnostic accuracy
of 93.5%.18 Possible motion artifacts were reduced by a 3D regis-
tration algorithm; contrast-enhancing lesions were detected by a seg-
mentation technique with an adaptive threshold.18 For morphologic
characterization of detected lesions, the CAD system extracted
13 parameters: volume, maximum and minimum diameter, surface
area, surface-to-volume ratio, compactness, characteristic of margin,
homogeneity, average signal intensity, deviation of signal intensities,
presence of spiculations, adjacent vessels, or central necrosis.18
These parameters were used to provide morphologic descriptors of
masses according to the BI-RADS MRI lexicon and were included in
the final lesions’ classification of the CAD system.18
The signal intensity time curves, achieved by CAD analysis,
were divided in an initial phase during the first 2 postcontrast se-
quences (graduated in 50% intervals of relative signal increase) and
a postinitial phase (continuous increase, plateau phenomenon, and
washout curve).9,11,18 The CAD system performed the dynamic
analysis by calculating signal intensity time curves of the whole
lesions, considering average signal intensity values, and the hot spot
regions, focusing on the location within the lesions (3  3 voxels)
with the highest signal enhancement during the first 2 post-
contrast sequences. Signal intensity time curves were displayed for
the whole lesions and the hot spot regions. For the final lesions’
classification, the following 8 dynamic parameters were additionally
calculated for the entire lesions and the hot spot regions: relative
enhancements (1Y5) between precontrast and each of the 5 postcontrast
sequences, maximum peak value of the signal intensity time curve,
relative signal increase within the first 2 postcontrast sequences, and
presence of washout sign. All extracted morphologic and dynamic
parameters were integrated for final lesions’ classification by the
CAD system; this calculated morpho-dynamic index (MDI) assessed
the probability of detected lesions to be malignant, ranging from
0% to 100%.18
Statistical Evaluation
The statistical analysis, including sample size calculation for
valid contrast media comparison, was scheduled and approved by a
statistician experienced in this field. The evaluations of the MRI
examinations using gadoteric acid versus gadobutrol were compared
with each other and correlated with the gold standard of histopath-
ologic findings. Statistical analysis was performed by using SPSS
version 17.0 for Windows (SPSS, Chicago, IL). The prevalence of
all morphologic and dynamic parameters was determined for both
MRI examinations. Student t tests were used to examine significant
differences between means of 2 samples with normal distribution.
For analyzing further possible differences, Wilcoxon rank sum tests
were calculated for ordinal data, and Pearson W2 tests were per-
formed for nominal data. For correlation analyses, Pearson (interval
parameters), Spearman rank (ordinal parameters), and Cramer V
coefficients (nominal data) were used. Receiver operating charac-
teristic analysis was performed to calculate the diagnostic accuracy
(area under the receiver operating characteristic curve) of the breast
MRI examinations. P values G0.05 (2-sided) were considered in all
statistical tests to indicate significances.
RESULTS
Patients and Histopathology
Forty-seven women with histopathologically verified mass
lesions were enrolled in the study; in the intraindividual contrast
media comparison, solely the histopathologically confirmed mass
lesions were considered. If the patients presented additional lesions
that were not histopathologically proven after the MRI examina-
tions, these lesions were not included in the comparison study. Two
of 47 patients had to be excluded, as they refused the second MRI
examination. Thus, 45 women fulfilled the inclusion criteria (n = 23
group A, n = 22 group B). The mean (SD) time interval between the
2 MRI examinations was 2.1 (1.2) days; the exact intervals were as
follows: 1 day, n = 13 patients; 2 days, n = 22; 3 days, n = 6; 4 days,
n = 2; 5 days, n = 1, and 7 days, n = 1. The 45 patients had a mean
(SD) age of 49.9 (12.1) years (range, 30Y70 years); 23 women
(51.1%) were premenopausal and 22 (48.9%) were postmenopausal.
The x-ray mammographic and ultrasonographic findings were
categorized as BI-RADS 4 in 27 of 45 patients (60.0%) and as 5 in
18 of 45 patients (40.0%). As all women had BI-RADS categoriza-
tion 4 or 5 on conventional imaging modalities, they could not dis-
continue possible hormonal medication for a longer time interval
before DCE-MRI to avoid retarding possible cancer treatment initi-
ation. Thus, 12 women received hormonal medication directly before
the MRI examinations (8 patients contraceptives and 4 hormone
replacement treatment). In 37 patients, malignant lesions were identi-
fied, which presented as masses; histopathology found invasive breast
cancer in 35 of 37 women and ductal carcinoma in situ in 2 of 37 pa-
tients. Four of 37 patients revealed bifocal, unilateral, invasive carci-
nomas. Thus, 41 mass lesions were histopathologically confirmed as
TABLE 1. Histologic Characteristics of Mass Breast Lesions
No. Lesions
Malignant lesions (n = 41)
Invasive ductal carcinoma 32
Well differentiated (G1) 4
Moderately differentiated (G2) 19
Poorly differentiated (G3) 9
Invasive lobular carcinoma 5
Well differentiated (G1) 1
Moderately differentiated (G2) 4
Invasive papillary carcinoma (moderately differentiated, G2) 1
Invasive mucinous carcinoma (moderately differentiated, G2) 1
Ductal carcinoma in situ 2
Intermediate grade (G2) 1
High grade (G3) 1
Benign lesions (n = 10)
Fibroadenoma 6
Adenosis 2
Atypical ductal hyperplasia 1
Papilloma 1
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malignant in 37 patients. Histologic types and tumor grading of these
41 malignant lesions are summarized in Table 1. Regarding breast
cancer therapy, more than half of 37 patients (n = 20; 54.1%)
underwent breast conservation followed by radiation. Ten women
(27.0%) received mastectomy, and 18.9% (n = 7) received
neoadjuvant chemotherapy with subsequent breast surgery.
Eight of 45 patients presented benign mass lesions, which
were histologically confirmed after the second DCE-MRI exami-
nation. Two patients had histopathologically confirmed malignant
and benign mass lesions. One mass lesion (atypical ductal hyper-
plasia) was surgically removed, as the 58-year-old patient underwent
mastectomy because of invasive ductal, G2 carcinoma in the same
breast. A 39-year-old woman received breast conservation because
of invasive ductal, G3 carcinoma in the left breast and synchronous
surgical extirpation of a fibroadenoma in the contralateral breast.
Thus, 10 benign mass lesions could be included with different his-
topathologic entities, as shown in Table 1.
Lesion Detection and Size
Thirty-nine of 41 malignant and all 10 benign mass lesions
were detected by the CAD method on the MRI examinations with
gadoteric acid and also with gadobutrol, corresponding to a detec-
tion rate each of 96.1% (49 detected of 51 malignant and benign
lesions). Two malignancies were missed by the CAD technique on
both MRI examinations (identical lesions by gadoteric acid and
gadobutrol). Both lesions could visually be observed by the human
readers with gadoteric acid and gadobutrol. One missed lesion
(7 mm mean size on MRI) was an invasive ductal cancer lesion (G3)
in a 63-year-old patient (contrast medium group B) with dense breast,
experiencing bifocal carcinoma, whereas her second, 12-mm-sized
cancer lesion was detected by CAD on both examinations. The
missed lesion presented an initial signal increase of 50% to 100%
followed by continuous enhancement, assessed by manual region
of interest analysis, on both MRI examinations, similar to the sur-
rounding dense glandular breast tissue. The second missed lesion by
CAD was an invasive ductal cancer (G3; 13 mm mean size on MRI)
in a 37-year-old patient (group A) who received hormonal contra-
ceptives and revealed severe BE (grade 2) by using gadoteric acid
and gadobutrol. The lesion demonstrated an initial signal increase
of 100% to 150% followed by plateau phenomenon, measured
by manual region of interest analysis, on both MRI examinations.
The automated lesion detection was hampered because of the se-
vere BE in this patient.
The remaining 44 patients in whom histopathologically veri-
fied lesions could be detected by the CAD system revealed similar
BE for gadoteric acid and gadobutrol. On both MRI examinations,
10 of 44 women (22.7%) presented moderate BE (grade 1) and 7 of
44 patients (15.9%) demonstrated distinct BE (grade 2). However,
BE was not strong enough to impair the automated lesion detection
in these patients.
Assessment of lesion diameters by the CAD method and by
the observers resulted in slightly lower sizes of the 49 detected mass
lesions for gadoteric acid compared with gadobutrol (Table 2).
These size differences between the 2 MRI examinations were not
significant, neither for CAD nor for visual analysis (Student t tests;
P 9 0.05). For lesions that were surgically removed subsequently
to the MRI examinations (n = 35), mean diameters were compared
with histologically determined sizes. The MRI examinations with
gadoteric acid resulted in lower, not significantly different, as-
sessments compared with the histologically verified sizes; by using
gadobutrol, the assessments were slightly, not significantly, higher
(Table 2). As shown in Figure 1, MRI size assessments by using
gadoteric acid and gadobutrol are both in good accordance with
histopathologically verified diameters of breast lesions.
Dynamic Lesion Characterization
As the CAD system provided a very differentiated dynamic
analysis, performing separate evaluation for whole lesion and hot spot
region, Tables 3 to 5 demonstrate the CAD evaluations in detail. The
initial signal increase of all, malignant, and benign lesions differed
between the 2 distinct MRI examinations, with lower values using
gadoteric acid than gadobutrol for the entire lesions (Fig. 2) and the hot
spot regions. These differences reached significance for the entire
lesions and hot spot regions of all masses (n = 49; Table 3) and the
malignancies (n = 39; Table 4), but not for the benign lesions solely
(n = 10; Table 5). Focusing on postinitial enhancement courses, MRI
examinations with gadoteric acid revealed more washout curves and
fewer continuous increases compared with gadobutrol (Tables 3Y5).
These differences were significant for the hot spot regions of all lesions
and the malignant masses (Tables 3 and 4).
TABLE 2. Assessed Sizes of Mass Breast Lesions
Mean, mm Median, mm SD, mm Interquartile Range, mm
All lesions (n = 49)
CAD evaluation
MRI examinations with gadoteric acid 25.0 21.0 13.0 21.0
MRI examinations with gadobutrol 26.6 23.0 13.7 18.5
Visual evaluation
MRI examinations with gadoteric acid 25.3 21.0 13.5 19.0
MRI examinations with gadobutrol 26.4 22.0 13.5 19.0
Surgically removed lesions (n = 35)
Histologically verified size 26.4 22.0 14.3 20.0
CAD evaluation
MRI examinations with gadoteric acid 25.4 21.0 13.3 21.0
MRI examinations with gadobutrol 27.0 22.0 13.2 16.0
Visual evaluation
MRI examinations with gadoteric acid 25.7 22.0 13.3 17.0
MRI examinations with gadobutrol 26.8 22.0 12.9 13.0
CAD indicates computer-assisted diagnosis; MRI, magnetic resonance imaging.
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Morphologic Lesion Characterization
The morphologic description by the CAD system was highly
consistent with the assessment of the human readers. Regarding
the shape of the 49 malignant and benign masses, Spearman rank
correlation coefficient was 0.839 for gadoteric acid (P G 0.001) and
0.823 for gadobutrol (P G 0.001). The margins of the 49 lesions,
assessed by the readers, also showed high consistency with the
CAD evaluation: Spearman rank correlation coefficient rs = 0.856
(P G 0.001) for gadoteric acid and rs = 0.863 (P G 0.001)
for gadobutrol. The correlation coefficient between human and
CAD assessment of the internal enhancement of the 49 lesions
was Cramer V = 0.781 (P G 0.001) for gadoteric acid and Cramer
V = 0.798 (P G 0.001) for gadobutrol.
As the morphologic description of breast lesions is commonly
performed in clinical routine by visual, not by CAD, evaluation, the
findings of the 2 human observers are presented in detail. The
morphologic parameters of the 10 histologically verified benign le-
sions were determined identically by the human readers on both MRI
examinations (Fig. 3). Their shape was assessed as follows: n = 7
round/oval and n = 3 lobulated. Six benign lesions presented smooth
and 4 showed irregular margins. The internal enhancement of the
benign lesions was determined as homogeneous (n = 5), heteroge-
neous (n = 3), and dark internal septations (n = 2).
In contrast to the benign lesions, some of the 39 malignant
masses showed different morphologic descriptions on the examina-
tions with gadoteric acid versus gadobutrol, as analyzed by the CAD
system and the human observers. Regarding shape, 4 of 39 malig-
nancies (10.3%) were classified differently by the human readers:
2 lesions were determined as round/oval by using gadoteric acid and
as irregular with gadobutrol, and 2 lesions were defined as lobulated
with gadoteric acid and as irregular with gadobutrol. The differences
in the shape assessment were not significant (Table 6). However,
the margins of the malignancies were determined as significantly
different between the 2 MRI examinations by the observers (Ta-
ble 6); descriptions of margins were discrepant for 9 of 39 (23.1%)
malignant lesions by using gadoteric acid versus gadobutrol: smooth
versus spiculated, n = 6; smooth versus irregular, n = 1 (Fig. 2); and
irregular versus spiculated, n = 2. Regarding the parameter internal
enhancement pattern, 6 malignancies (15.4%) were determined
differently (P 9 0.05; Table 6); their assessment was as follows for
gadoteric acid versus gadobutrol: rim enhancement versus hetero-
geneous, n = 3; heterogeneous versus rim enhancement, n = 2; and
dark internal septations versus enhancing internal septations, n = 1.
Classification of Lesions
The diagnostic accuracy of gadoteric acid and gadobutrol was
similar between the 2 MRI examinations for the human lesions’
classification based on the BI-RADS categorization. Compared with
gadoteric acid, the MDI calculations of the CAD system were
slightly higher by using gadobutrol for all lesions, the malignancies,
and the benign lesions (Table 7, Fig. 4). However, the mean differ-
ences between the MDI calculations of gadoteric acid versus
gadobutrol were not significant (all lesions, P = 0.710; malignan-
cies, P = 0.661; and benign lesions, P = 0.871). Distinguishing
malignant from benign lesions by the MDI, the diagnostic accuracy
was also similar for gadoteric acid (93.2%; 95% confidence interval,
FIGURE 1. Box plots present the size assessments of lesions,
which were surgically removed subsequently to the MRI
examinations (n = 35). The lesion diameters have been
determined for both MRI examinations (with gadoteric acid
and gadobutrol) automatically by the CAD system and visually
by the human readers and compared with the
histopathologically verified sizes.
TABLE 3. Signal Intensity Time Courses of 49 Histologically
Verified Mass Lesions (n = 39 Malignant, n = 10 Benign) as
Calculated by the CAD System
Dynamic Signal
Intensity Time Courses
MRI
Examinations
With
Gadoteric Acid
MRI
Examinations
With
Gadobutrol P (2-Sided)
Entire lesions
Initial phase G0.05
50%Y100% 7 (14.3) 2 (4.1)
100%Y150% 11 (22.4) 11 (22.4)
150%Y200% 13 (26.5) 9 (18.4)
200%Y250% 10 (20.4) 12 (24.5)
250%Y300% 6 (12.2) 8 (16.3)
300%Y400% 2 (4.1) 3 (6.1)
400%Y500% 0 (0.0) 2 (4.1)
9500% 0 (0.0) 2 (4.1)
Postinitial phase NS
Continuous increase 13 (26.5) 18 (36.7)
Plateau phenomenon 17 (34.7) 15 (30.6)
Washout curve 19 (38.8) 16 (32.7)
Hot spot regions
Initial phase G0.05
50%Y100% 1 (2.0) 0 (0.0)
100%Y150% 3 (6.1) 2 (4.1)
150%Y200% 8 (16.3) 5 (10.2)
200%Y250% 12 (24.5) 9 (18.4)
250%Y300% 13 (26.5) 8 (16.3)
300%Y400% 9 (18.4) 15 (30.6)
400%Y500% 1 (2.0) 5 (10.2)
9500% 2 (4.1) 5 (10.2)
Postinitial phase G0.05
Continuous increase 7 (14.3) 14 (28.6)
Plateau phenomenon 13 (26.5) 15 (30.6)
Washout curve 29 (59.2) 20 (40.8)
Numbers in parentheses are percentages; the percentages may not add up
to 100.0% because of rounding. The differences were evaluated by using
Wilcoxon rank sum tests.
CAD indicates computer-assisted diagnosis; MRI, magnetic resonance
imaging; NS, nonsignificant.
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86.1%Y100.0%) and gadobutrol (93.1%; 95% confidence interval,
85.9%Y100.0%).
DISCUSSION
To optimize the diagnostic yield of breast DCE-MRI, the fo-
cus of investigations has mainly set on imaging parameters and
technical advances.4,12,35Y40 Considerably fewer publications have
compared different contrast media for breast MRI using intra-
individual, prospective, blinded study designs.21Y24 Differences in
dynamic signal enhancement, correct detection, and classification of
malignant and benign breast lesions have been reported between
gadobenate dimeglumine (Gd-BOPTA) and Gd-DTPA.21Y23 The
higher signal intensities for gadobenate dimeglumine are supposed
to rely mainly on its approximately 2-fold higher T1 relaxivity com-
pared with gadopentetate dimeglumine.21Y23,41,42 In our clinical trial,
gadobutrol reached higher initial signal intensities, statistically signifi-
cant for all and also exclusively the malignant lesions. One explanation
might be the approximately 1.5-fold higher T1 relaxivity of gadobutrol
compared with gadoteric acid. The doubled Gd concentration per unit
volume is another possible reason; the 1.0 M chelate gadobutrol has
been shown to allow a narrower bolus profile, resulting in an increased,
more compact intravascular concentration and, consecutively a sharper
bolus peak during first pass compared with 0.5 M agents.32,43,44 In our
investigation, the effect of the higher gadobutrol concentration was
presumably diminished by the administration of a larger amount of
sodium chloride solution.
High contrast medium concentration exists early in the
extravascular extracellular space (EES) of tumors, as small-
molecular MRI contrast media with weights less than 1000 Da,
such as gadoteric acid and gadobutrol, rapidly diffuse from intra-
vascular to EES, especially through malignant microvessels with
endothelial leakages.25,45 In general, the principal pathway and
mechanism of breast tumor enhancement are assumed to be similar for
all small-molecular contrast media.10,25,45 The higher signal enhance-
ment of gadobutrol, both during first pass and lasting up to several
minutes, resulting in more continuous increases and fewer washout
curves, is in concordance with published results. Anzalone et al46
found significantly higher signal enhancement and contrast-to-noise
ratio of cerebral neoplasms for gadobutrol than gadoteric acid
several minutes after contrast medium administration in an intra-
individual comparison. Attenberger et al47 analyzed signal en-
hancement in a rat brain glioma model; signal-to-noise ratio and
contrast-to-noise ratio in the tumor were higher for gadobutrol
compared with gadoteric acid and gadopentetate dimeglumine at
5 time points (1 minute postcontrast and 4 consecutive 2-minutes’
intervals thereafter).
TABLE 4. Signal Intensity Time Courses of 39 Malignant Mass
Lesions as Calculated by the CAD System
Dynamic Signal
Intensity Time Courses
MRI
Examinations
With
Gadoteric Acid
MRI
Examinations
With
Gadobutrol
P
(2-Sided)
Entire lesions
Initial phase G0.05
50%Y100% 4 (10.3) 1 (2.6)
100%Y150% 7 (17.9) 5 (12.8)
150%Y200% 12 (30.8) 7 (17.9)
200%Y250% 9 (23.1) 12 (30.8)
250%Y300% 5 (12.8) 8 (20.5)
300%Y400% 2 (5.1) 2 (5.1)
400%Y500% 0 (0.0) 2 (5.1)
9500% 0 (0.0) 2 (5.1)
Postinitial phase NS
Continuous increase 6 (15.4) 9 (23.1)
Plateau phenomenon 14 (35.9) 14 (35.9)
Washout curve 19 (48.7) 16 (41.0)
Hot spot regions
Initial phase G0.01
100%Y150% 2 (5.1) 1 (2.6)
150%Y200% 4 (10.3) 2 (5.1)
200%Y250% 10 (25.6) 5 (12.8)
250%Y300% 12 (30.8) 8 (20.5)
300%Y400% 8 (20.5) 14 (35.9)
400%Y500% 1 (2.6) 4 (10.3)
9500% 2 (5.1) 5 (12.8)
Postinitial phase G0.05
Continuous increase 2 (5.1) 7 (17.9)
Plateau phenomenon 10 (25.6) 13 (33.3)
Washout curve 27 (69.2) 19 (48.7)
Numbers in parentheses are percentages; the percentages may not add up
to 100.0% because of rounding. The differences were evaluated by using
Wilcoxon rank sum tests.
CAD indicates computer-assisted diagnosis; MRI, magnetic resonance
imaging; NS, nonsignificant.
TABLE 5. Signal Intensity Time Courses of 10 Benign Mass Lesions
as Calculated by the CAD System
Dynamic Signal
Intensity Time Courses
MRI
Examinations
With
Gadoteric Acid
MRI
Examinations
With
Gadobutrol
P
(2-Sided)
Entire lesions
Initial phase NS
50%Y100% 3 (30.0) 1 (10.0)
100%Y150% 4 (40.0) 6 (60.0)
150%Y200% 1 (10.0) 2 (20.0)
200%Y250% 1 (10.0) 0 (0.0)
250%Y300% 1 (10.0) 0 (0.0)
300%Y400% 0 (0.0) 1 (10.0)
Postinitial phase NS
Continuous increase 7 (70.0) 9 (90.0)
Plateau phenomenon 3 (30.0) 1 (10.0)
Hot spot regions
Initial phase NS
50%Y100% 1 (10.0) 0 (0.0)
100%Y150% 1 (10.0) 1 (10.0)
150%Y200% 4 (40.0) 3 (30.0)
200%Y250% 2 (20.0) 4 (40.0)
250%Y300% 1 (10.0) 0 (0.0)
300%Y400% 1 (10.0) 1 (10.0)
400%Y500% 0 (0.0) 1 (10.0)
Postinitial phase NS
Continuous increase 5 (50.0) 7 (70.0)
Plateau phenomenon 3 (30.0) 2 (20.0)
Washout curve 2 (20.0) 1 (10.0)
Numbers in parentheses are percentages. The differences were evaluated by
using Wilcoxon rank sum tests.
CAD indicates computer-assisted diagnosis; MRI, magnetic resonance
imaging; NS, nonsignificant.
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The persistent higher signal intensities after gadobutrol ad-
ministration might be caused partly by differences in T1 relaxivities;
however, relaxivity is not the only property of a contrast agent that
influences imaging parameters. The higher rate of continuous in-
creases accompanied by fewer washout curves can pharmacokinetically
be explained that gadobutrol accumulates to a higher extent in the
EES of breast carcinomas than gadoteric acid. As the molecular
weight of gadobutrol (605 Da) is only slightly higher compared with
that of gadoteric acid (559 Da), this property might be of minor im-
portance for EES accumulation.25,33,44 Unlike gadobenate dimeglumine,
gadoteric acid and gadobutrol are generally considered as non-protein-
binding.25,32,33,48 However, Vogler et al48 identified an amount of
2.7% protein binding in gadobutrol, although calculations of low
protein binding are prone to substantial measurement errors.48 If,
in fact, gadobutrol possesses some weak protein binding in contrast
to gadoteric acid and thus interacts with proteins of the extracellular
tumoral matrix, this mechanism could also contribute to the postinitial
signal intensity differences.
The major cause for the postinitial differences, significant for
all and the malignant lesions, however, might be the negative charge
of gadoteric acid versus the neutrality of gadobutrol. The extracel-
lular matrix of malignant and some benign tumors possess glycos-
aminoglycan macromolecules with negatively ionized side groups.49
Imaging studies of articular cartilage, whose extracellular matrix is
rich in glycosaminoglycans, revealed that the concentration of gly-
cosaminoglycans is negatively correlated with signal enhancement,
if negatively charged contrast media are used.50,51 In contrast, neu-
tral agents slowly diffuse into cartilage tissue independently of gly-
cosaminoglycan concentration.51 The negative charge of gadoteric
acid might therefore be particularly responsible for lower accumu-
lation in the tumoral EES. This hypothesis is in concordance with
the findings of a recently published intraindividual comparison of
gadobutrol versus gadobenate dimeglumine; Pediconi et al24 found
more continuous signal intensity time curves of malignant breast
lesions by using gadobutrol compared with the ionic gadobenate
dimeglumine, evaluated by 2 readers: 28.6% versus 15.7% (reader 1)
and 35.2% versus 28.4% (reader 2). However, these differences did
not reach statistical significance in this multicenter investigation.24
The higher signal enhancement and the increased accumula-
tion in the tumoral EES of gadobutrol might be responsible for
the slightly larger lesion diameters (with very good accordance to
histopathologically verified sizes) and the higher number of breast
carcinomas with spiculated margins combined with fewer smooth
boundaries. As a consequence, the malignant infiltration of surrounding
tissues, resulting in ill-defined boundaries, should be clearly visualized
with gadobutrol. This finding is in accordance with Pediconi et al,24 who
reported that significantlymoremalignancieswere assessed as non-mass-
enhancements (boundaries more ill-defined compared with masses) for
gadobutrol than for gadobenate dimeglumine. The final lesion classi-
fication by the CAD system (MDI) did not differ between gadobutrol
and gadoteric acid, as the higher initial signal increase and the
morphologic shape description of malignancies were assessed in a
FIGURE 2. MRI examinations with gadoteric acid (A) and gadobutrol (B) of a 58-year-old patient with moderately differentiated,
invasive ductal carcinoma in the left breast. The first postcontrast subtraction images show lower initial signal increase of the entire
lesion for gadoteric acid (A) compared with gadobutrol (B). The morphologic characterization of the carcinoma has been
determined by the human observers in both examinations with an oval shape and a heterogeneous signal enhancement. The
margin has been assessed by the observers as smooth with gadoteric acid (A) and as irregular by using gadobutrol (B). In addition,
both MRI examinations demonstrate a lymph node, suspicious for malignant infiltration, in the left axillary. The CAD system
displayed signal intensity time curve of the whole lesion (C), demonstrating the relative signal intensity in percentage over time in
seconds, with an initial enhancement of greater than 250% followed by washout curve (signal decrease, 910%) in the MRI
examination with gadoteric acid (continuous curve); the signal intensity time curve of the whole lesion was displayed as initial
enhancement of greater than 300%, followed by plateau phenomenon (signal intensity, T10%) in the MRI examination with
gadobutrol (discontinuous curve). The probability of malignancy (MDI) was assessed by the CAD system as 98% in the MRI
examination with gadoteric acid (D) and as 100% by using gadobutrol (E).
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higher rate as typically malignant by using gadobutrol; however,
gadoteric acid resulted in higher quantity of characteristic washout
curves of malignant lesions.
Despite the standardized interpretation of breast MR images
by using the internationally accepted BI-RADS atlas, the MRI
technical protocol does vary considerably between institutions
FIGURE 3. MRI examinations with gadoteric acid (A) and gadobutrol (B) of a 39-year-old patient with histologically verified
fibroadenoma in the right breast. In the first postcontrast subtraction images (A, gadoteric acid; B, gadobutrol), the morphologic
characterization of the fibroadenoma has been determined by the human observers in both examinations with an oval shape, a
smooth margin, and a heterogeneous signal enhancement. The CAD system displayed the signal intensity time curve of the whole
lesion (C), demonstrating the relative signal intensity in percentage over time in seconds, with an initial enhancement between 50%
and 100%, followed by continuous increase (signal increase, 910%) in theMRI examination with gadoteric acid (continuous curve);
the signal intensity time curve of the whole lesion was displayed as initial enhancement between 100% and 150%, followed by
continuous increase in the MRI examination with gadobutrol (discontinuous curve). The probability of malignancy (MDI) was
assessed by the CAD system as 25% in the MRI examination with gadoteric acid (D) and as 28% by using gadobutrol (E).
TABLE 6. Morphologic Parameters of 39 Malignant Mass Lesions as Determined by the Human Observers
Morphologic BI-RADS Descriptors MRI Examinations With Gadoteric Acid MRI Examinations With Gadobutrol P (2-Sided)
Shape NS
Round/oval 11 (28.2) 9 (23.1)
Lobulated 17 (43.6) 15 (38.5)
Irregular 11 (28.2) 15 (38.5)
Margin G0.05
Smooth 10 (25.6) 3 (7.7)
Irregular 19 (48.7) 18 (46.2)
Spiculated 10 (25.6) 18 (46.2)
Internal enhancement NS
Homogeneous 3 (7.7) 3 (7.7)
Heterogeneous 26 (66.7) 27 (69.2)
Rim enhancement 6 (15.4) 5 (12.8)
Dark internal septations 2 (5.1) 1 (2.6)
Enhancing internal septations 2 (5.1) 3 (7.7)
Central enhancement 0 (0.0) 0 (0.0)
Numbers in parentheses are percentages; the percentages may not add up to 100.0% because of rounding. The differences were evaluated by using Wilcoxon
rank sum tests (shape and margin) and Pearson W2 test (internal enhancement).
BI-RADS indicates Breast imaging reporting and data system; MRI, magnetic resonance imaging; NS, nonsignificant.
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worldwide, such as time resolution, 2D versus 3D dynamic scan-
ning, and use of parallel imaging or fat suppression.38,39 Analyzing
3 different MR imaging protocols, Jansen et al38 found significantly
different dynamic initial and postinitial characteristics of breast le-
sions. Thus, the characterization of breast lesions and description
of possible BE can vary due to technical MRI parameters (eg, 2D
versus 3D, duration of dynamic T1-weighted sequences), the injec-
tion bolus (eg, amount of saline flush, flow rate, pause after injec-
tion), and patient conditions (eg, application of hormone therapy,
cardiac insufficiency). Additionally, the reported differences for
contrast media in published intraindividual comparisons21Y24 and
the findings of our intraindividual comparison study, with identical
technical parameters and patient conditions of both MRI examina-
tions (with gadoteric acid and gadobutrol), revealed that the type of
contrast medium can also influence the characterization of breast
lesions. Using the same type and dose of contrast agents is therefore
particularly important in follow-up MRI examinations, such as mon-
itoring the efficacy of neoadjuvant chemotherapy.
There are certain limitations of our investigation. The number
of patients and particularly the included benign lesions are of small
quantity, as the reference standard was histopathologic verification of
masses; lesions that presented as obviously benign on MRI were not
histopathologically proven after the MRI examinations and could
therefore not be included. The included patient collective is highly
selected and small; the findings of this study have to be validated
using larger patient cohorts in the future. Another important limita-
tion is the exclusion of non-mass lesions because of configurations of
the used CAD system, which results in selection bias and requires
further investigations with inclusion of non-mass lesions. To mini-
mize technical effects on dynamic and morphologic MRI parameters,
for example, due to multicenter differences in sequence parameters,
we decided to implement unique MRI protocol in a single center with
consistent clinical, radiological, and histopathologic data. However,
because of varying breast sizes, the FOV of the MRI examinations
differed between patients, which might influence the morphologic
characterization of lesions, although the FOV remained constant
within the 2 MRI examinations (with gadoteric acid and gadobutrol)
of the same patient. The size of the included masses was quite large,
with mean diameter of approximately 25 mm; however, this lesion
size is in the range of published studies, evaluating breast MR images
by CAD systems.15 There exists a lack of data for small lesions, as
the correct detection and characterization of small breast lesions
remain a specific challenge for CAD systems on breast MRI.52
Further limitations of this investigation are that premenopausal
and postmenopausal women were included; patients could not dis-
continue possible hormonal medication for a longer time interval,
and premenopausal women did not undergo breast DCE-MRI at the
exactly same time points of their menstrual cycle. In a recently
published trial, premenopausal women presented higher BE than
postmenopausal women did.53 However, these study conditions are
prevalent in typical clinical settings. The time interval between the
2 MRI examinations was 7 days or less, mostly 1 or 2 days; possible
effects of different menstrual cycle phases or other hormonal effects
cannot be fully excluded. As BE did not differ between the 2 MRI
examinations, hormonal effects might be similar, and thus, the MRI
examinations with gadoteric acid versus gadobutrol could be reli-
ably compared.
CONCLUSIONS
The findings of this prospective investigation indicate that the
macrocyclic contrast media gadoteric acid and gadobutrol can be
accurately used for breast MRI. Some morphologic and dynamic
characterization of histologically verified breast lesions by using
gadoteric acid versus gadobutrol differed in an intraindividual, blinded
comparison, assessed by human observers and an automatic CAD
system. However, the final classification of the breast lesions and the
diagnostic accuracy of the MRI examinations were similar between
TABLE 7. Morpho-Dynamic Index of Mass Lesions as Calculated by the CAD System
Mean, % Median, % SD, % Interquartile Range, %
All lesions (n = 49)
MRI examinations with gadoteric acid 73.9 82.0 24.5 34.0
MRI examinations with gadobutrol 75.7 84.0 23.7 26.5
Malignant lesions (n = 39)
MRI examinations with gadoteric acid 82.4 87.0 16.2 23.0
MRI examinations with gadobutrol 83.9 89.0 15.2 17.0
Benign lesions (n = 10)
MRI examinations with gadoteric acid 40.9 38.5 24.1 42.0
MRI examinations with gadobutrol 42.7 41.0 24.9 48.8
CAD indicates computer-assisted diagnosis; MRI, magnetic resonance imaging; NS, nonsignificant.
FIGURE 4. Box plots present the calculation of the probability
of malignancy (by the MDI) for malignant (n = 39) and benign
(n = 10) lesions by the CAD system. The lesion classifications by
the MDI were performed for the MRI examinations with
gadoteric acid versus gadobutrol.
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gadoteric acid and gadobutrol. Besides the standardization of technical
MRI and injection bolus parameters as well as imaging interpretation,
the standardization of the applied contrast medium seems to be im-
portant for reproducible characterization of breast lesions, particularly
with regard to follow-up MRI examinations, such as monitoring the
efficacy of neoadjuvant chemotherapy.
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